Jim Shannon: To ask the Secretary of State for Health and Social Care, what discussions he has had with pharmaceutical companies on reducing the cost of the drug liothyronine.
Lord Hunt of Kings Heath: To ask Her Majesty's Government what action they are taking to negotiate a reduction of the cost of liothyronine (T3) for use in primary care.
Elaine Smith: ...important aspect for those needing it to survive: “The Scottish Government’s position is that treatment for Hypothyroidism in Scotland should be consistent with the BTA guidance in relation to Liothyronine (T3) and clinicians in Scotland can prescribe T3 where it is safe and clinically appropriate, on the advice of a consultant in endocrinology.” The minister backed that up in his...
Elaine Smith: ...disorders? Does she agree that it is unacceptable for any Scottish national health service board to refuse patients, particularly those under the care of an endocrinologist, their prescriptions for liothyronine medication, as currently happens? Will she ask the Cabinet Secretary for Health and Sport to intervene to ensure that my constituents and other thyroid sufferers are not stopped by...
Layla Moran: To ask the Secretary of State for Health and Social Care, what recent steps he has taken to increase access to liothyronine on the NHS for people with hypothyroidism.
Steve McCabe: ...and Social Care, what discussions his Department has had with the Competition and Markets Authority on the publication of the final outcome of the investigation into Concordia and their pricing of Liothyronine (T3) medication.
Lord Hunt of Kings Heath: To ask Her Majesty's Government whether they will commission research on the impact of the withdrawal of liothyronine (T3) and its subsequent replacement with T4 on (1) the health and well being of patients, and (2) the cost to the NHS.
Lord O'Shaughnessy: ...by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is...
Lord Hunt of Kings Heath: To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 4 July (HL8857), whether patient groups were consulted in relation to the discussions on Liothyronine (T3) at the meetings of the Regional Medicines Optimisation Committee held in January and May 2018.
Lord Hunt of Kings Heath: To ask Her Majesty's Government what assessment they have made of the risk to patients of being denied access to liothyronine (T3) where they had previously achieved good health outcomes when using the medicine.
Lord Hunt of Kings Heath: To ask Her Majesty's Government whether they intend to review local and regional guidance by NHS bodies which do not follow current national guidance in relation to the prescribing of liothyronine (T3).
Lord Hunt of Kings Heath: To ask Her Majesty's Government whether they will ensure that the appropriate funds will be made available when an endocrinologist has prescribed liothyronine (T3) for an NHS patient.
Lord Hunt of Kings Heath: To ask Her Majesty's Government whether they will take steps to withdraw PrescQIPP guidance to Clinical Commissioning Groups in the East of England on prescribing liothyronine (T3) as it has not been updated to reflect current national guidelines.
Lord Hunt of Kings Heath: ...July (HL8980, HL8981, HL8982 and HL8983), what action they are taking to ensure that NHS England makes clear to Clinical Commissioning Groups that the national guidelines on access for patients to Liothyronine (T3) are expected to be fully followed.
Lord Hunt of Kings Heath: ...to the Written Answer by Lord O'Shaughnessy on 4 July (HL8854), why the minutes of the meeting of the Regional Optimisation Committee South held in May 2018 in relation to the discussion on Liothyronine (T3) have yet to be published.
Lord Hunt of Kings Heath: To ask Her Majesty's Government what action they propose to ensure that the Brighton and Sussex University Hospitals NHS Trust withdraws its policy of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients.
Lord Hunt of Kings Heath: To ask Her Majesty's Government whether they have held discussions with NHS England about why NHS bodies in Wessex are developing guidelines on the use of liothyronine which are at variance with national guidelines issued by NHS England.
Lord O'Shaughnessy: .... The drug levothyroxine, T4, is beneficial for the majority of patients with hypothyroidism, as we have heard, but it does not treat the condition in all patients. For some, the alternative drug, liothyronine, commonly known as T3, which is the subject of this evening’s debate, is a treatment which better alleviates their symptoms. NHS England has set out that liothyronine should be...
Steve Brine: ...for the majority of patients with the condition but does not treat the condition in all patients. For some, the alternative drug at the centre of the right hon. Gentleman’s opening remarks—liothyronine—better alleviates symptoms. Let me say up front that, if people have a clinical need for a medicine, it is right that they get the most appropriate medicine for their condition. It is...
Steve Brine: ...dispensed in the community in England British National Formulary Chemical Name 2015 2016 2017 Levothyroxine Sodium £104,482,222 £97,074,190 £86,942,415 Levothyroxine Sodium and Liothyronine £665,394 £1,000,049 £1,270,675 Liothyronine Sodium £22,188,778 £32,804,312 £30,237,512 Total £127,336,394 £130,878,552 £118,450,601 Source: Prescription Cost...